13 December 2013
Details
FMC Corporation
has signed a definitive agreement
to sell its Peroxygens business
to affiliates of One Equity Partners,
the private investment arm of J.P. Morgan Chase & Co.
The transaction,
valued at for approximately $200 million,
is expected to close in the first quarter of 2014.
FMC Peroxygens, although a successful business,
is not a strategic fit with the company's growth platforms.
In April, FMC simplified its organizational structure
to focus on 3 core business segments that
better reflect the markets where the company
* participates and leads, and
* where it expects to grow in the future.
FMC Corporation,
Pierre Brondeau, President, CEO and Chairman
- This transaction will help unlock the growth potential of
the Peroxygens business with focused attention and investment,
while allowing FMC to direct our resources to core segments in
* crop protection,
* health and nutrition technologies,
* alkali chemicals and lithium.
WWW.CHEMWINFO.COM BY KHUN PHICHAI